BioSpace News Archive

Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Health and Human Services Officer of Inspector General report (OIG) on prescription drug rebates in Medicare Part D.

Zimmer Biomet Holdings, Inc., a global leader in musculoskeletal healthcare, will participate in the 2019 Cantor Global Healthcare Conference at the InterContinental New York Barclay Hotel in New York.

Aimmune Therapeutics, Inc. announced that the Allergenic Products Advisory Committee convened by the U.S. Food and Drug Administration voted to support the use of AR101 in children and teens with peanut allergy.

FINNEA Group, LLC is pleased to announce the successful growth financing capital raise by Xoran Holdings LLC.

Abionic SA announced the successful completion of its multi-center observational study using Abionic’s novel point-of-care Pancreatic Stone Protein sepsis test on the abioSCOPE® platform.

Halozyme Therapeutics, Inc. announced that the global phase III FeDeriCa study conducted by Genentech, a member of the Roche Group, met its primary endpoint.

Study Highlights the Utility of Bacterial Fluorescence Imaging to Provide Real-Time Information to Clinicians on a Wound’s Bacterial Burden that Significantly Impacted Treatment Decisions

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented new results from an analysis of the UK Biobank – a prospective cohort study with genetic, physical, and health data on approximately 500,000 individuals across the United Kingdom – demonstrating a significant association of the V122I mutation, a highly prevalent mutation in the transthyretin (TTR) gene, with a clinical diagnosis of polyneuropathy.

Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) is pleased to announce that it has been named as a winner in the 2019 ANZLF Trans-Tasman Innovation & Growth Awards.

IRRAS AB, a commercial stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced that Vinny Podichetty VP, Clinical, Regulatory Affairs & Quality has resigned for personal reasons, and two key appointments to drive IRRAS’ continued growth.